FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company
First written in FY2022-Q1. 12 of 22 entries say "Restated". Latest entry: 2026-10-01.
The whole theme swung hardest in 2025: 9 of 54 companies on the "Worse" side.
6 other companies' latest entry also says "Cited as achieved".
- 2026-10-01Cited as achievedGovernance
「2025年度を最終年度とする「中期経営計画 2025」では、売上高 700 億円、営業利益率 8％、ROE8％という目標を掲げ、そのすべてを達成することができました。」
中期経営計画2025の目標達成を経営トップメッセージおよび統合報告書で実績として引用している。 - FY2026RaisedAnnual report
「Our group formulated a medium-term management plan covering the period from April 2021 through the end of March 2026, and achieved its FY2025 targets of ¥70.0 billion in sales, an 8% operating margin and 8% ROE. For FY2028, we have set targets of ¥85.0 billion in sales, a 10% operating margin and 10% ROE.」
The previous FY2025 targets of ¥70.0 billion in sales, an 8% operating margin and 8% ROE were achieved, and new FY2028 targets of ¥85.0 billion in sales, a 10% operating margin and 10% ROE were established. - FY2026-H1RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company, are reiterated. - FY2025AdvancedAnnual report
「Our group has formulated a medium-term management plan covering the period from April 2021 through the end of March 2026. For FY2025, the final year of the plan, we have set targets of ¥70.0 billion in sales, an operating margin of 8% and ROE of 8%.」
The FY2025 targets are reiterated, together with FY2024 sales of ¥64,139 million, an operating margin of approximately 8.3% and ROE of 8.02%. Sales were below ¥70.0 billion, while the operating margin and ROE reached the target levels. - FY2025-H1RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company, are reiterated. - FY2024AdvancedAnnual report
「For the current consolidated fiscal year, group sales increased by ¥2,381 million from the previous consolidated fiscal year to ¥62,843 million, up 3.9% year on year. Operating income increased by ¥1,392 million to ¥6,500 million, up 27.3%, and the operating margin was 10.3%.」
Against the FY2025 targets, FY2023 sales were ¥62,843 million, the operating margin was 10.3% and ROE was 13.0%. Sales fell short of the ¥70.0 billion target, while the operating margin and ROE exceeded the 8% targets. - FY2024-Q3RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company built on a specialty pharma platform, are reiterated. - FY2024-Q2RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company built on a specialty pharma platform, are reiterated. - FY2024-Q1RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company, are reiterated. - FY2023RestatedAnnual report
「Our group has formulated a medium-term management plan covering the period from April 2021 through the end of March 2026. For FY2025, the final year of the plan, we have set targets of ¥70.0 billion in sales, an operating margin of 8% and ROE of 8%.」
The FY2025 targets of ¥70.0 billion in sales, an 8% operating margin and 8% ROE are reiterated in the annual report. - FY2023-Q3RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company built on a specialty pharma platform, are reiterated. - FY2023-Q2RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company built on a specialty pharma platform, are reiterated. - FY2023-Q1RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company built on a specialty pharma platform, are reiterated. - FY2022RestatedAnnual report
「Our group has formulated a medium-term management plan covering the period from April 2021 through the end of March 2026. For FY2025, the final year of the plan, we have set targets of ¥70.0 billion in sales, an operating margin of 8% and ROE of 8%.」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the plan period through the end of March 2026, are reiterated. - FY2022-Q3RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term plan’s targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company built on a specialty pharma platform, are reiterated. - FY2022-Q2RestatedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The targets of ¥70.0 billion in FY2025 sales, an 8% operating margin and 8% ROE, together with the policy of becoming a total healthcare company, are reiterated in the same wording. - FY2022-Q1First statedAnnual report
「Under our medium-term management plan launched in FY2021, we are working to build on the foundation established to date and achieve our FY2025 targets, the final year of the plan: sales of ¥70.0 billion, an operating margin of 8%, and return on equity (ROE) of 8%, as we work toward realizing the vision of a “total healthcare company built on a specialty pharma platform.”」
The medium-term management plan launched in FY2021 sets out, for the first time, numerical targets for sales, operating margin and ROE through FY2025, as well as the company’s vision.